BACKGROUND AND PURPOSE: Apolipoprotein E (apoE) epsilon 4 allele has been associated with a high risk for coronary heart disease. Increased frequency of the epsilon 4 allele has also been reported in patients with late-onset familial and sporadic Alzheimer's disease (AD). The aim of this study was to investigate the degree of coronary and cerebral atherosclerosis in a neuropathologically verified series of AD patients with different apoE genotypes. In addition, we studied the relationship between the degree of coronary and cerebral atherosclerosis and the extent of beta-amyloid (A beta) accumulation. METHODS: We studied 38 subjects (32 patients with definite AD and 6 age-matched control subjects) for whom postmortem autopsy delay was less than 8 hours. ApoE genotypes were identified through Hha I digestion of the polymerase chain reaction-amplified samples. We used A beta immunohistochemistry to detect diffuse and neuritic plaques as well as cerebrovascular amyloid. The degree of coronary and cerebral atherosclerosis was rated as none, mild, moderate, or severe. RESULTS: The apoE genotypes of the AD patients were epsilon 4/4 2, epsilon 3/4 19, epsilon 3/3 9, and epsilon 3/2 2. We found more severe atherosclerosis of the coronary vessels among AD patients with the apoE epsilon 4 allele compared with those AD patients without the epsilon 4 allele (chi 2 = 4.1, df = 1, P < .05). The extent of cerebral atherosclerosis did not differ among AD subgroups with and without the epsilon 4 allele. The degree of coronary or cerebral atherosclerosis was not related to the amount of amyloid accumulation in the frontal and temporal cortices or in the hippocampal structures. CONCLUSIONS: This study confirms the association of apoE epsilon 4 allele with coronary atherosclerosis in AD patients.
BACKGROUND AND PURPOSE:Apolipoprotein E (apoE) epsilon 4 allele has been associated with a high risk for coronary heart disease. Increased frequency of the epsilon 4 allele has also been reported in patients with late-onset familial and sporadic Alzheimer's disease (AD). The aim of this study was to investigate the degree of coronary and cerebral atherosclerosis in a neuropathologically verified series of ADpatients with different apoE genotypes. In addition, we studied the relationship between the degree of coronary and cerebral atherosclerosis and the extent of beta-amyloid (A beta) accumulation. METHODS: We studied 38 subjects (32 patients with definite AD and 6 age-matched control subjects) for whom postmortem autopsy delay was less than 8 hours. ApoE genotypes were identified through Hha I digestion of the polymerase chain reaction-amplified samples. We used A beta immunohistochemistry to detect diffuse and neuritic plaques as well as cerebrovascular amyloid. The degree of coronary and cerebral atherosclerosis was rated as none, mild, moderate, or severe. RESULTS: The apoE genotypes of the ADpatients were epsilon 4/4 2, epsilon 3/4 19, epsilon 3/3 9, and epsilon 3/2 2. We found more severe atherosclerosis of the coronary vessels among ADpatients with the apoE epsilon 4 allele compared with those ADpatients without the epsilon 4 allele (chi 2 = 4.1, df = 1, P < .05). The extent of cerebral atherosclerosis did not differ among AD subgroups with and without the epsilon 4 allele. The degree of coronary or cerebral atherosclerosis was not related to the amount of amyloid accumulation in the frontal and temporal cortices or in the hippocampal structures. CONCLUSIONS: This study confirms the association of apoE epsilon 4 allele with coronary atherosclerosis in ADpatients.
Authors: M S Beeri; M Rapp; J M Silverman; J Schmeidler; H T Grossman; J T Fallon; D P Purohit; D P Perl; A Siddiqui; G Lesser; C Rosendorff; V Haroutunian Journal: Neurology Date: 2006-05-09 Impact factor: 9.910
Authors: Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh Journal: Neuropathology Date: 2015-01-26 Impact factor: 1.906
Authors: Gai L McMichael; Catherine S Gibson; Paul N Goldwater; Eric A Haan; Kevin Priest; Gustaaf A Dekker; Alastair H MacLennan Journal: Hum Genet Date: 2008-09-23 Impact factor: 4.132
Authors: Mark Yarchoan; Sharon X Xie; Mitchel A Kling; Jon B Toledo; David A Wolk; Edward B Lee; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Steven E Arnold Journal: Brain Date: 2012-11-30 Impact factor: 13.501
Authors: C M Barbagallo; F Polizzi; M Severino; M Rizzo; N Vivona; F Onorato; R Caldarella; A B Cefalù; D Noto; A Notarbartolo; M R Averna Journal: Eur J Epidemiol Date: 2001 Impact factor: 8.082
Authors: Thomas G Beach; Chera L Maarouf; Reed G Brooks; Scophil Shirohi; Ian D Daugs; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; LihFen Lue; Alex E Roher Journal: BMC Geriatr Date: 2011-01-25 Impact factor: 3.921
Authors: Joseph O Ojo; Jon M Reed; Gogce Crynen; Prashanthi Vallabhaneni; James Evans; Benjamin Shackleton; Maximillian Eisenbaum; Charis Ringland; Anastasia Edsell; Michael Mullan; Fiona Crawford; Corbin Bachmeier Journal: Front Aging Neurosci Date: 2021-05-17 Impact factor: 5.750